Huntsman (HUN)
(Delayed Data from NYSE)
$24.18 USD
-0.03 (-0.12%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $24.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.18 USD
-0.03 (-0.12%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $24.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
Zacks.com highlights: Medifast, Continental Building Products, Huntsman, Logitech International and Allison Transmission Holdings
by Zacks Equity Research
Zacks.com highlights: Medifast, Continental Building Products, Huntsman, Logitech International and Allison Transmission Holdings
Valmont (VMI) Buys Walpar, Expands in Sign Structures Market
by Zacks Equity Research
The acquisition strengthens Valmont's (VMI) foothold in the sign structures market.
Andersons (ANDE) Q2 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Andersons (ANDE) anticipated to benefit from strong domestic and export demand despite the impact of current tariffs and trade disputes.
Valmont (VMI) Buys Derit, Enters Lattice Structures Market
by Zacks Equity Research
Valmont (VMI) is poised to benefit from Derit's 40,000 metric tons of lattice manufacturing capacity.
5 Top Momentum Stocks Powered by Driehaus Strategy
by Zacks Equity Research
Richard Herman Driehaus who is a well-known American businessman and fund manager, developed an investment approach based on the buy high and sell higher rule.
Is Huntsman (HUN) a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Huntsman (HUN) have what it takes? Let's find out.
Are Investors Undervaluing Huntsman (HUN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Huntsman's (HUN) Earnings and Revenues Top Estimates in Q2
by Anindya Barman
Huntsman's (HUN) Q2 results were driven by strong performance across its businesses.
Huntsman (HUN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Huntsman (HUN) delivered earnings and revenue surprises of 16.09% and 5.62%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Chemical Stock Earnings to Watch on Jul 31: ECL, HUN & More
by Anindya Barman
Chemical stocks reporting earnings on Jul 31 are unlikely to impress.
Top Ranked Value Stocks to Buy for July 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, July 17th:
HUN or PX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HUN vs. PX: Which Stock Is the Better Value Option?
Huntsman (HUN) Up 37% in a Year: What's Behind the Rally?
by Anindya Barman
Forecast-topping earnings performance, efforts to expand specialty businesses and focus on free cash flow generation have contributed to the rally in Huntsman's (HUN) shares.
Sherwin-Williams to be Aided by Valspar Buyout, Cost Control
by Zacks Equity Research
Sherwin-Williams (SHW) should benefit from synergies of the Valspar acquisition and cost-reduction initiatives amid raw material cost pressure.
Here's Why You Should Add Chemours (CC) to Your Portfolio
by Zacks Equity Research
Strong fundamentals and upbeat prospects make Chemours (CC) an attractive choice for investment.
Ashland to Hike Maleic Anhydride Prices in North America
by Zacks Equity Research
Ashland's (ASH) decision to raise prices is driven by raw material cost inflation in feed stocks along with high demand and limited supplies for maleic anhydride.
Celanese Set to Raise Prices of Acetyl Intermediate Products
by Zacks Equity Research
Celanese (CE) is taking appropriate pricing actions amid a volatile raw material pricing environment that are likely to lend support to margins.
5 Reasons to Add Innospec (IOSP) to Your Portfolio Now
by Zacks Equity Research
Strong fundamentals and upbeat prospects make Innospec (IOSP) an attractive choice for investment.
4 Reasons to Add Reliance Steel (RS) Stock to Your Portfolio
by Zacks Equity Research
Robust earnings performance, optimistic outlook, improving metal pricing environment and strong momentum across auto and aerospace make Reliance Steel (RS) a promising bet now.
LyondellBasell Strategic Plans Bode Well: Should You Hold?
by Zacks Equity Research
Strategic buyouts and capacity expansion projects strengthen LyondellBasell's (LYB) portfolio. However, weak ethylene prices and raw material inflation remain a concern.
Westlake Chemical Hits New 52-Week High: What's Driving it?
by Zacks Equity Research
Forecast-topping Q1 earnings performance and an upbeat outlook are contributing to a rally in Westlake Chemical's (WLK) shares.
Arconic (ARNC) Plunges 31.6% YTD: What's Pulling It Down?
by Zacks Equity Research
Arconic's (ARNC) stock performance is plagued with pricing woes, instability in certain end markets and a high leverage.
4 Reasons to Add FMC Corp (FMC) Stock to Your Portfolio Now
by Zacks Equity Research
Robust earnings performance, upbeat outlook and strong momentum in Lithium unit make FMC Corp (FMC) a promising bet now.
Cabot (CBT) to Exhibit Activated Carbon Products at ACHEMA
by Zacks Equity Research
Cabot (CBT) is set to showcase Norit range from activated carbon families at ACHEMA 2018, Germany, that will assist in catalyst application.
LyondellBasell Gets China Antitrust Nod for A. Schulman Buy
by Zacks Equity Research
The $2.25 billion acquisition doubles the size of LyondellBasell's (LYB) existing compounding business.